Likewise, the incidence of thyroid irAE in the present study was higher than that of a meta-analysis of clinical trials of anti-PD-1 and anti-PD-L1 antibodies; hypothyroidism was 6.07% and thyrotoxicosis was 2.82% [15]. Here, PDCD1 is linked to thyrotoxicosis.